IRIX NASDAQ
IRIDEX Corporation
1W: +2.9%
1M: -10.8%
3M: -42.6%
YTD: -45.0%
1Y: -43.1%
3Y: -69.5%
5Y: -91.4%
$0.64
+0.01 (+1.77%)
Weekly Expected Move ±5.8%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (37)
IRIDEX (NASDAQ:IRIX) Shares Cross Below 200-Day Moving Average – Here’s Why
IRIDEX (IRIX) Q2 2026 Earnings Call Transcript
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
IRIDEX Corporation Q2 2026 Earnings Call Summary
Iridex reaffirms 2026 revenue guidance of $51m-$53m while highlighting working-capital build tied to headquarters relocation
Iridex Reports Second Quarter 2026 Financial Results
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
IRIDEX Corporation Q1 2026 Earnings Call Summary
Iridex reaffirms $51M-$53M 2026 revenue outlook while targeting $600,000 annualized cost reduction
Iridex (IRIX) Q1 2026 Earnings Transcript
Iridex Reports First Quarter 2026 Financial Results
Iridex Reports First Quarter 2026 Financial Results
Earnings Scheduled For May 19, 2026
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX
Top Analyst Reports for Microsoft, AbbVie & BHP
IRIDEX (NASDAQ:IRIX) Stock Crosses Below 200-Day Moving Average – Should You Sell?
IRIDEX (NASDAQ:IRIX) Stock Crosses Below 200-Day Moving Average – Should You Sell?
12 Health Care Stocks Moving In Tuesday's After-Market Session
IRIDEX (NASDAQ:IRIX) Share Price Passes Below 200 Day Moving Average – Here’s Why
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
12 Health Care Stocks Moving In Friday's Intraday Session
Iridex outlines $51M-$53M 2026 revenue target as manufacturing shift and cost cuts drive positive cash flow
IRIDEX (IRIX) Q4 2025 Earnings Call Transcript
IRIDEX GAAP EPS of -$0.01 beats by $0.01, revenue of $14.7M misses by $0.04M
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Earnings Scheduled For March 26, 2026
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Iridex Announces Plans to Relocate Headquarters
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025
Zacks Initiates Coverage of Iridex With Neutral Recommendation
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
Iridex to Present at the Sidoti Year-End Virtual Investor Conference